Related Experiment Video
Updated: Jun 3, 2026
06:15
Evaluation of Bioenergetic Function in Cerebral Vascular Endothelial Cells
Published on: November 19, 2016
Targeting endothelial and myocardial dysfunction with tetrahydrobiopterin
An L Moens1, Rinrada Kietadisorn, Judy Y Lin
1Maastricht University Medical Centre, Cardiovascular Research Institute Maastricht, Dept. of Cardiology, Maastricht, The Netherlands. an.moens@mumc.nl
Journal of Molecular and Cellular Cardiology
|April 5, 2011
Summary
Tetrahydrobiopterin (BH(4)) is vital for nitric oxide synthase and acts as an antioxidant. Reduced BH(4) contributes to cardiovascular diseases, but its therapeutic use for these conditions requires further investigation.
Area of Science:
- Biochemistry
- Cardiovascular Biology
- Pharmacology
Background:
- Tetrahydrobiopterin (BH(4)) is a crucial cofactor for enzymes like nitric oxide synthase (NOS) and aromatic amino acid hydroxylases.
- BH(4) also functions as an endogenous antioxidant, protecting cells from reactive oxygen and nitrogen species.
- Diminished BH(4) bioavailability is implicated in endothelial dysfunction, hypertension, and cardiac remodeling through eNOS uncoupling.
Purpose of the Study:
- To review the pathophysiologic role of reduced BH(4) bioavailability.
- To explore the molecular mechanisms governing BH(4) metabolism.
- To discuss the potential therapeutic applications and challenges of BH(4) as an NOS-modulating drug.
Main Methods:
- Literature review of experimental studies in humans and animals.
- Analysis of molecular mechanisms regulating BH(4) metabolism.
- Evaluation of clinical data on synthetic BH(4) use.
Main Results:
- Decreased BH(4) bioavailability contributes to endothelial dysfunction and cardiovascular pathologies.
- Synthetic BH(4) shows promise in preclinical models for ameliorating cardiovascular issues.
- Clinical translation of BH(4) therapy for cardiovascular diseases has yielded mixed results.
Conclusions:
- Reduced BH(4) bioavailability is a significant factor in cardiovascular disease development.
- While promising, the therapeutic efficacy and optimal use of BH(4) in human cardiovascular conditions require further research.
- Understanding BH(4) metabolism and its role in NOS function is key for developing effective NOS-modulating therapies.
Related Concept Videos
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...